## **Aviad Tsherniak**

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4213951/aviad-tsherniak-publications-by-year.pdf

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 74                | 8,686                 | 39                  | 82              |
|-------------------|-----------------------|---------------------|-----------------|
| papers            | citations             | h-index             | g-index         |
| 82<br>ext. papers | 12,789 ext. citations | <b>22.5</b> avg, IF | 5.22<br>L-index |

| #              | Paper   | IF   | Citations |
|----------------|---|------|-----------|
| 74             | Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects <i>Genome Biology</i> , <b>2021</b> , 22, 343   | 18.3 | 8         |
| 73             | Integrated cross-study datasets of genetic dependencies in cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 1661  | 17.4 | 17        |
| 7 <sup>2</sup> | A first-generation pediatric cancer dependency map. <i>Nature Genetics</i> , <b>2021</b> , 53, 529-538  | 36.3 | 21        |
| 71             | Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. <i>Nature Genetics</i> , <b>2021</b> , 53, 1196-1206   | 36.3 | 9         |
| 70             | Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. <i>Cell Reports</i> , <b>2021</b> , 34, 108532 | 10.6 | 15        |
| 69             | An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. <i>Cancer Cell</i> , <b>2021</b> , 39, 240-256.e11  | 24.3 | 29        |
| 68             | Global computational alignment of tumor and cell line transcriptional profiles. <i>Nature Communications</i> , <b>2021</b> , 12, 22   | 17.4 | 19        |
| 67             | Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. <i>Nature Cancer</i> , <b>2020</b> , 1, 235-248  | 15.4 | 137       |
| 66             | Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. <i>Nature Genetics</i> , <b>2020</b> , 52, 1208-1218  | 36.3 | 63        |
| 65             | Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. <i>Nature Communications</i> , <b>2020</b> , 11, 4296                | 17.4 | 37        |
| 64             | Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. <i>Cell Reports</i> , <b>2020</b> , 33, 108493                     | 10.6 | 7         |
| 63             | Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. <i>Cell Reports</i> , <b>2019</b> , 28, 2331-2344.e8                       | 10.6 | 20        |
| 62             | Mitochondrial metabolism promotes adaptation to proteotoxic stress. <i>Nature Chemical Biology</i> , <b>2019</b> , 15, 681-689  | 11.7 | 62        |
| 61             | Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , <b>2019</b> , 10, 2400                  | 17.4 | 18        |
| 60             | Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , <b>2019</b> , 569, 503-508   | 50.4 | 962       |
| 59             | The landscape of cancer cell line metabolism. <i>Nature Medicine</i> , <b>2019</b> , 25, 850-860  | 50.5 | 188       |
| 58             | Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. <i>Cancer Research</i> , <b>2019</b> , 79, 2564-2579  | 10.1 | 18        |

| 57 | WRN helicase is a synthetic lethal target in microsatellite unstable cancers. <i>Nature</i> , <b>2019</b> , 568, 551-556  | 50.4          | 137 |
|----|---|---------------|-----|
| 56 | MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. <i>Cancer Research</i> , <b>2019</b> , 79, 2404-2414  | 10.1          | 24  |
| 55 | Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. <i>Nature Communications</i> , <b>2019</b> , 10, 5817   | 17.4          | 70  |
| 54 | Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. <i>Cancer Discovery</i> , <b>2018</b> , 8, 108-125          | 24.4          | 67  |
| 53 | Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma.<br>Journal of Experimental Medicine, <b>2018</b> , 215, 2137-2155                     | 16.6          | 43  |
| 52 | Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. <i>Nature Genetics</i> , <b>2018</b> , 50, 1240-1246             | 36.3          | 94  |
| 51 | Genetic and transcriptional evolution alters cancer cell line drug response. <i>Nature</i> , <b>2018</b> , 560, 325-330   | 50.4          | 379 |
| 50 | GeNets: a unified web platform for network-based genomic analyses. <i>Nature Methods</i> , <b>2018</b> , 15, 543-54   | <b>6</b> 21.6 | 36  |
| 49 | CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 446-462                                 | 15.9          | 72  |
| 48 | Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. <i>Nature Communications</i> , <b>2018</b> , 9, 4610 | 17.4          | 155 |
| 47 | Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. <i>Nature Communications</i> , <b>2018</b> , 9, 5450  | 17.4          | 83  |
| 46 | Mutational processes shape the landscape of TP53 mutations in human cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 1381-1387  | 36.3          | 165 |
| 45 | Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. <i>Cell Systems</i> , <b>2018</b> , 6, 555-568.e7                | 10.6          | 65  |
| 44 | Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , <b>2018</b> , 9, 2024                                  | 17.4          | 54  |
| 43 | Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 937-943                           | 36.3          | 35  |
| 42 | mutant tumors depend on oxoglutarate dehydrogenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E3434-E3443         | 11.5          | 24  |
| 41 | Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. <i>Nature Communications</i> , <b>2017</b> , 8, 15403                                    | 17.4          | 65  |
| 40 | Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. <i>Nature Genetics</i> , <b>2017</b> , 49, 1779-1784       | 36.3          | 740 |

| 39 | Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. <i>Cell Stem Cell</i> , <b>2017</b> , 21, 547-555.e8          | 18   | 43  |
|----|---|------|-----|
| 38 | A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. <i>Cell Systems</i> , <b>2017</b> , 5, 485-497.e3 | 10.6 | 14  |
| 37 | Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. <i>Cell Systems</i> , <b>2017</b> , 5, 105-118.e9   | 10.6 | 27  |
| 36 | Defining a Cancer Dependency Map. <i>Cell</i> , <b>2017</b> , 170, 564-576.e16  | 56.2 | 844 |
| 35 | PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 4613-4625  | 10.1 | 21  |
| 34 | Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. <i>ELife</i> , <b>2017</b> , 6,  | 8.9  | 49  |
| 33 | Functional Genomic Characterization of Cancer Genomes. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , <b>2016</b> , 81, 237-246   | 3.9  | 11  |
| 32 | Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.<br>Cancer Discovery, <b>2016</b> , 6, 914-29  | 24.4 | 343 |
| 31 | Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. <i>Nature Chemical Biology</i> , <b>2016</b> , 12, 102-8  | 11.7 | 51  |
| 30 | MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. <i>Science</i> , <b>2016</b> , 351, 1214-8   | 33.3 | 248 |
| 29 | High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 419-23                   | 44.5 | 127 |
| 28 | Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 207-15        | 6.6  | 16  |
| 27 | Integrated genetic and pharmacologic interrogation of rare cancers. <i>Nature Communications</i> , <b>2016</b> , 7, 11987   | 17.4 | 32  |
| 26 | Characterizing genomic alterations in cancer by complementary functional associations. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 539-46   | 44.5 | 57  |
| 25 | SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. <i>Nature Medicine</i> , <b>2015</b> , 21, 1491-6  | 50.5 | 252 |
| 24 | Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. <i>Oncotarget</i> , <b>2015</b> , 6, 30178-93          | 3.3  | 51  |
| 23 | Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. <i>Scientific Data</i> , <b>2014</b> , 1, 140035     | 8.2  | 251 |
| 22 | SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. <i>Cancer Cell</i> , <b>2013</b> , 24, 738-50   | 24.3 | 111 |

| 21 | ECatenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. <i>Cell</i> , <b>2013</b> , 153, 267-270   | 56.2 | 6   |  |
|----|---|------|-----|--|
| 20 | ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. <i>Genome Research</i> , <b>2013</b> , 23, 665-78  | 9.7  | 93  |  |
| 19 | Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 517-25  | 15.9 | 371 |  |
| 18 | ECatenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. <i>Cell</i> , <b>2012</b> , 151, 1457-73   | 56.2 | 522 |  |
| 17 | Cancer vulnerabilities unveiled by genomic loss. <i>Cell</i> , <b>2012</b> , 150, 842-54  | 56.2 | 163 |  |
| 16 | Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1424-30  | 2.2  | 513 |  |
| 15 | Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 12372-7 | 11.5 | 321 |  |
| 14 | Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1415-23   | 2.2  | 58  |  |
| 13 | Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration   |      | 2   |  |
| 12 | Multiplexed single-cell profiling of post-perturbation transcriptional responses to define cancer vulnerabilities and therapeutic mechanism of action   |      | 3   |  |
| 11 | Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells   |      | 1   |  |
| 10 | Gene expression has more power for predicting in vitro cancer cell vulnerabilities than genomics  |      | 12  |  |
| 9  | Post-perturbational transcriptional signatures of cancer cell line vulnerabilities  |      | 1   |  |
| 8  | Global computational alignment of tumor and cell line transcriptional profiles  |      | 2   |  |
| 7  | Integrated cross-study datasets of genetic dependencies in cancer   |      | 3   |  |
| 6  | Open Community Challenge Reveals Molecular Network Modules with Key Roles in Diseases   |      | 10  |  |
| 5  | Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasets   |      | 2   |  |
| 4  | Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lir   | nes  | 88  |  |

| 3 | Non-oncology drugs are a source of previously unappreciated anti-cancer activity     | 6 |
|---|--|---|
| 2 | Pan-cancer single cell RNA-seq uncovers recurring programs of cellular heterogeneity | 9 |
| 1 | Chronos: a CRISPR cell population dynamics model                                     | 2 |